Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans.
- Patent protected plant-based formulations (under license)
- Proven to kill SARS-CoV-2 in early stage lab testing
- Platform technology - Potential for a range of lung diseases
- Working with leading research organisations
There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).
Our team were conducting research into wound care with another biomedical firm but, when COVID-19 hit, they looked to pivot the technology through Inspira to tackle this challenge. They discovered that the molecules in the formulations might be able to attack the SARS-CoV-2 spike proteins.
In lab tests, our formulations killed over 95% of the SARS-CoV-2 virus; now we want to test whether a COVID-19 patient could safely inhale our formulations directly into the lungs as an effective treatment.
So far we've secured cornerstone investment from biotech angel investors & a Singaporean VC, we’re now offering retail investors the opportunity to invest alongside them! Funds raised will be used to test our formulations as a potential new drug. This will include further laboratory analysis, safety testing, & preparation for human trials.
We believe our technology has further potential for a number of other respiratory infections. We plan to test our formulations against cystic fibrosis, influenza & the common cold in coming months.
COVID-19 thrives in a crowd, wouldn't it be amazing if the crowd could come together to fight back against the pandemic.
Co-Founder & CEO
Rory founded Inspira to see if small biotech could find a cure for deadly respiratory diseases, including COVID-19. A qualified lawyer with experience in corporate finance, start-ups & commercial law. Previously founded Metan Polska, a European clean-tech company that was awarded a €5 mil R&D grant in 2020. Rory is driven by both social benefits & shareholder returns.
Nick Woolf (PT)
Co-Founder & Director
Nick is an accomplished leader in life sciences with experience in biotech & investment banking. Nick was previously CEO of AusCann Group (ASX:AC8) & has held senior executive roles with SUDA Pharmaceuticals & Oxford BioMedica. MA (Oxon) in Chemistry from Oxford University.
Dr Giuseppe Trigiante (PT)
A specialist biochemist with an inventive mindset, Giuseppe has been instrumental in developing Inspira’s core technology. He's the inventor of a process that preserves the activity of the active molecules in liquid solution. He's led the company’s scientific team since Inspira’s inception. PhD from Stanford University.
Dr Neil Rzechorzek (PT)
A skilled protein scientist with over 15 years of hands-on expertise, Neil advises on the key experiments that drive our technology forward, leveraging his practical expertise in biotech consultancy & entrepreneurship. PhD from the Institute of Cancer Research, University of London.